Dear Healthcare Professional, Biogen ldec and Elan are writing to inform you of new safety information regarding TYSABRI" (natalizumab). The full Prescribing Information has been revised to add to the   more »

A letter posted to the Food and Drug Administration's Web site says that patients taking Tysabri, which is manufactured at a facility in Research Triangle Park, have developed signs of liver injury as soon as six days after taking their first dose.   more »

The results showed that treatment with COPAXONE® (glatiramer acetate injection) reduced the risk of developing clinically definite MS (CDMS) by 44 percent versus placebo, and   more »

Prolonged therapy with interferon beta (IFNbeta) often leads to the development of anti-IFNbeta binding antibodies (BAbs). A subset of the BAbs is of a neutralizing nature (neutralizing antibodies, NAbs) and   more »

Q. Where can I call to get more information about Tysabri? The Tysabri Care Program is a registry that supports the safe and effective use of Tysabri. Its goals are to: · To inform people about the risks and benefits of Tysabri prior to treatment   more »

Q. Will my insurance cover the cost of Tysabri? A. According to Biogen Idec Canada, most private insurers are now reimbursing the cost of Tysabri. Generally insurance companies require prior authorization before they will   more »

Q. What is Tysabri (pronounced Tie-SAB-bree) and how does it work? A. Tysabri (whose scientific name is natalizumab, pronounced: nat-tal-IZ-zue-mab) is a laboratory-produced monoclonal antibody. It was formerly called Antegren. It had been approved for   more »

There are 6 US Food and Drug Administration (FDA)-approved DMTs in the United States at this time. These DMTs are IFN beta-1a (intramuscular or subcutaneous), IFN beta-1b, glatiramer acetate, mitoxantrone, and natalizumab. All of   more »

Although most hypersensitive reactions to natalizumab (Tysabri) occur within hours of the first dose, such responses may be delayed, according to   more »

natalizumab results in significant improvements in scores on health-related quality of life (QoL) questionnaires in patients    more »

To evaluate the safety and efficacy of long-term glatiramer acetate (GA) therapy, 46 patients with relapsing remitting multiple sclerosis (RRMS) were treated for up to 22 years in an ongoing, open-label   more »

Biogen Idec Inc. and PDL BioPharma, Inc. (PDL) announced that Phase 2 data demonstrated a significant reduction in new or enlarged gadolinium- enhancing lesions when daclizumab   more »

The glycoprotein integrin is expressed on the surface of these cells and plays a critical part in their adhesion to the vascular endothelium and migration into the parenchyma. Tysabri (Natalizumab) is an integrin antagonist that reduced the development of brain lesions in   more »

The two-year study showed that treatment with Betaseron delayed the time to a second clinical event by one year compared to placebo. (1) BENEFIT is the only trial to demonstrate the   more »